One Year After DSLT Launch

Early users of Alcon’s Voyager share real-world experiences, discuss workflow strategies, and offer tips for efficiency and patient comfort.

By: Jim Gallagher, senior managing editor

Glaucoma Physician January 1, 2026 Page(s): 10-13

Clinical Report: One Year After DSLT Launch

Overview

The Voyager Direct Selective Laser Trabeculoplasty (DSLT) platform has been successfully integrated into clinical practice, enhancing treatment accessibility for glaucoma patients. Early adopters report improved patient comfort and workflow efficiency, positioning DSLT as a valuable first-line therapy.

Background

Selective laser trabeculoplasty (SLT) is increasingly recognized as a first-line treatment for glaucoma, supported by major clinical guidelines. The introduction of the Voyager DSLT platform aims to streamline this procedure, making it more accessible and efficient for both patients and healthcare providers. Understanding real-world experiences with DSLT is crucial for optimizing its use in clinical settings.

Data Highlights

No numerical data provided in the source material.

Key Findings

The Voyager DSLT allows for fully automated, 360° treatment without the need for a gonioscopy lens.
DSLT is suitable for a broader range of patients compared to manual SLT, particularly those with challenging anatomical features.
Early users have adapted their techniques to enhance patient comfort and treatment efficiency.
Workflow strategies, such as preloading patient data and preparing instruments in advance, significantly reduce delays during procedures.
Real-world data indicate comparable success and intraocular pressure (IOP) lowering between DSLT and traditional SLT.

Clinical Implications

Healthcare providers should consider integrating the Voyager DSLT into their glaucoma treatment protocols to enhance patient comfort and streamline workflows. Training on the device's unique features and adapting techniques based on early user experiences can further improve outcomes.

Conclusion

The Voyager DSLT represents a significant advancement in glaucoma treatment, with early adopters reporting positive outcomes in patient care and procedural efficiency. Continued evaluation of its long-term effectiveness will be essential as more clinicians adopt this technology.

PentaVision

Glaucoma Physician